Literature DB >> 22009618

From liver cirrhosis to HCC.

Luigi Bolondi1, Laura Gramantieri.   

Abstract

Hepatocellular carcinoma represents the main cause of death in patients with Child-A cirrhosis. Surveillance programs aimed at the early diagnosis of hepatocellular carcinoma, at potentially treatable stages, are mandatory in Child-A cirrhotic patients and in Child-B cirrhotic patients, provided liver transplantation can be pursued. Surveillance allows stage migration and in definite subgroups of patients, it improves survival as well. Even though several circulating markers have been tested, none of them, including serum AFP determination, is actually recommended in the setting of surveillance. Thus ultrasound scan is the only recommended test, and it should be performed at 6-month intervals. Upon detection of a new nodule, a diagnostic algorithm based on the size of the nodule should be applied. In the western countries, the BCLC proposal is the most widely used and validated staging system and it helps to choice of the best treatment option even though each patient deserves a multidisciplinary evaluation due to the complexity of the coexistence of two diseases: hepatocellular carcinoma and liver cirrhosis.

Entities:  

Mesh:

Year:  2011        PMID: 22009618     DOI: 10.1007/s11739-011-0682-8

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  44 in total

Review 1.  Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.

Authors:  Kelly A Gebo; Geetanjali Chander; Mollie W Jenckes; Khalil G Ghanem; H Franklin Herlong; Michael S Torbenson; Samer S El-Kamary; Eric B Bass
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 2.  Proteomic applications for the early detection of cancer.

Authors:  Julia D Wulfkuhle; Lance A Liotta; Emanuel F Petricoin
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

3.  High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.

Authors:  M F Donato; E Arosio; E Del Ninno; G Ronchi; P Lampertico; A Morabito; M R Balestrieri; M Colombo
Journal:  Hepatology       Date:  2001-09       Impact factor: 17.425

4.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

Authors:  Franco Trevisani; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Luisa Benvegnù; Marco Zoli; Gian Luca Grazi; Poggio Paolo Del; NolfoMariaAnna Di; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

5.  Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Authors:  Ramón Vilana; Alejandro Forner; Luis Bianchi; Angeles García-Criado; Jordi Rimola; Carlos Rodríguez de Lope; María Reig; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

6.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

7.  Early hepatocellular carcinoma as an entity with a high rate of surgical cure.

Authors:  T Takayama; M Makuuchi; S Hirohashi; M Sakamoto; J Yamamoto; K Shimada; T Kosuge; S Okada; K Takayasu; S Yamasaki
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

8.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

9.  Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.

Authors:  Elisa Wurmbach; Ying-bei Chen; Greg Khitrov; Weijia Zhang; Sasan Roayaie; Myron Schwartz; Isabel Fiel; Swan Thung; Vincenzo Mazzaferro; Jordi Bruix; Erwin Bottinger; Scott Friedman; Samuel Waxman; Josep M Llovet
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  12 in total

1.  The role of serum biomarkers in hepatocellular carcinoma surveillance.

Authors:  Jorge A Marrero; Keith S Henley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

2.  CCAT1 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Huaqiang Zhu; Xu Zhou; Hong Chang; Hongguang Li; Fangfeng Liu; Chaoqun Ma; Jun Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC.

Authors:  Yunqing Chen; Ying Xu; Miaoxian Zhao; Yu Liu; Mingxing Gong; Cantao Xie; Hongkai Wu; Zhanhui Wang
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

5.  Identification of characteristic TRB V usage in HBV-associated HCC by using differential expression profiling analysis.

Authors:  Yingxin Han; Xing Liu; Yuqi Wang; Xiaolei Wu; Yanfang Guan; Hongmei Li; Xinchun Chen; Boping Zhou; Qing Yuan; Ying Ou; Renhua Wu; Wanqiu Huang; Yun Wang; Ming Zhang; Yinxin Zhang; Dongxing Zhu; Hongmei Zhu; Ling Yang; Xin Yi; Chen Huang; Jian Huang
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

6.  Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis.

Authors:  Yoon Ok Jang; Mee-Yon Cho; Chae-Ok Yun; Soon Koo Baik; Kyu-Sang Park; Seung-Kuy Cha; Sei Jin Chang; Moon Young Kim; Yoo Li Lim; Sang Ok Kwon
Journal:  Stem Cells Transl Med       Date:  2016-06-30       Impact factor: 6.940

7.  Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model.

Authors:  Yoon Ok Jang; Moon Young Kim; Mee Yon Cho; Soon Koo Baik; Youn Zoo Cho; Sang Ok Kwon
Journal:  BMC Gastroenterol       Date:  2014-11-25       Impact factor: 3.067

8.  Value of the 8-oxodG/dG ratio in chronic liver inflammation of patients with hepatocellular carcinoma.

Authors:  Pengcheng Li; Grant A Ramm; Graeme A Macdonald
Journal:  Redox Biol       Date:  2016-02-09       Impact factor: 11.799

9.  T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma.

Authors:  Kai-Rong Lin; Fei-Wen Deng; Ya-Bin Jin; Xiang-Ping Chen; Ying-Ming Pan; Jin-Huan Cui; Zhi-Xuan You; Huan-Wei Chen; Wei Luo
Journal:  Cancer Med       Date:  2018-06-26       Impact factor: 4.452

10.  Mesenchymal stem cells overexpressing hepatocyte nuclear factor-4 alpha alleviate liver injury by modulating anti-inflammatory functions in mice.

Authors:  Zhenxiong Ye; Wenfeng Lu; Lei Liang; Min Tang; Yunfeng Wang; Zhen Li; Heping Zeng; Aili Wang; Moubin Lin; Lei Huang; Hui Wang; Hai Hu
Journal:  Stem Cell Res Ther       Date:  2019-05-27       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.